Gout News and Research

Latest Gout News and Research

Dual-energy CT has potential to allow non-invasive diagnosis of gout, say radiologists

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC.

30 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, England.

22 Apr 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company's Biologics License Application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.

18 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

CUBN gene mutation linked with albuminuria in individuals with or without diabetes

A team of researchers from the United States and Europe has identified a single genetic mutation in the CUBN gene that is associated with albuminuria both with and without diabetes. Albuminuria is a condition caused by the leaking of the protein albumin into the urine, which is an indication of kidney disease.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.

25 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

Savient closes sale of $230M 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

4 Feb 2011

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of Notes, solely to cover over-allotments.

1 Feb 2011

Uric acid levels linked to severe osteoarthritis

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center.

19 Jan 2011

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron and Bayer HealthCare announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

18 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

Gout News and Research

Latest Gout News and Research

Dual-energy CT has potential to allow non-invasive diagnosis of gout, say radiologists

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

CUBN gene mutation linked with albuminuria in individuals with or without diabetes

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Savient launches KRYSTEXXA in the U.S.

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Savient closes sale of $230M 4.75% Convertible Senior Notes due 2018

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Uric acid levels linked to severe osteoarthritis

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

BioCryst reports positive results from peramivir Phase 3 study in influenza

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Gout News and Research

Latest Gout News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in